AC Immune (ACIU) Stock Price, News & Analysis

Company Overview

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins. AC Immune’s pipeline has included therapeutic vaccines, monoclonal antibodies, small-molecule drug candidates and positron emission tomography imaging agents designed to detect pathological proteins in the brain.

Founded in 2003, AC Immune conducts research and clinical development internationally and has established collaborations with major pharmaceutical companies, including Roche and Genentech. The company is led by Chief Executive Officer Andrea Pfeifer, who has been associated with AC Immune since its early development. AC Immune’s American depositary shares trade on the Nasdaq Capital Market under the symbol ACIU.

Key Stats

• Today's Range: $2.23 to $2.33
• 50-Day Range: $2.06 to $2.93
• 52-Week Range: $2.02 to $3.90
• Volume: 91,386 shs
• Average Volume: 265,679 shs
• Market Capitalization: $230.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Moderate Buy

AC Immune Stock Analysis - MarketRank™

AC Immune scored higher than 68% of companies evaluated by MarketBeat, and ranked 258th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AC Immune has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

AC Immune has a consensus price target of $7.50, representing about 228.2% upside from its current price of $2.29.

Amount of Analyst Coverage

AC Immune has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AC Immune are expected to grow in the coming year, from ($0.54) to $0.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AC Immune is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AC Immune is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AC Immune has a P/B Ratio of 6.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.04% of the float of AC Immune has been sold short.

Short Interest Ratio / Days to Cover

AC Immune has a short interest ratio ("days to cover") of 16.88, which indicates bearish sentiment.

Change versus previous month

Short interest in AC Immune has recently decreased by 9.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AC Immune does not currently pay a dividend.

Dividend Growth

AC Immune does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.42

News Sentiment

AC Immune has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for AC Immune this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added AC Immune to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AC Immune insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.60% of the stock of AC Immune is held by insiders.

Percentage Held by Institutions

51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACIU
• CIK: 1651625
• Web: www.acimmune.com
• Phone: (121) 345-9121
• Fax: 41-21-345-9120
• Employees: 106
• Year Founded: 2003

Price Target and Rating

• Average Price Target for AC Immune: $7.50
• High Price Target: $8.00
• Low Price Target: $7.00
• Potential Upside/Downside: +232.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 5.24
• P/E Growth: N/A
• Net Income: -$85.03 million
• Net Margins: -181.38%
• Pretax Margin: -1,796.18%
• Return on Equity: -105.25%
• Return on Assets: -25.04%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 0.85
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $19.81 million
• Price / Sales: 11.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.33 per share
• Price / Book: 6.83

Miscellaneous

• Outstanding Shares: 101,774,000
• Free Float: 97,092,000
• Market Cap: $229.50 million
• Optionable: Optionable
• Beta: 1.64